Glow-in-the-Dark dye could help surgeons spot brain tumors

NCT ID NCT07438860

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a fluorescent dye called SBK2-ICG in 12 adults with untreated malignant brain tumors. The dye is given before surgery to see if it can make tumor edges glow, helping surgeons remove as much tumor as possible while protecting healthy brain. The main goal is to check safety, with a secondary goal of seeing how well it works compared to an existing method.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SBK2-ICG (a fluorescent dye)
What this could lead to
If successful, this could help surgeons see tumor boundaries more clearly during brain surgery, potentially leading to more complete tumor removal while sparing healthy brain tissue.
What could go wrong
This is a very early Phase 1 safety study with only 12 participants. The dye may not work as hoped, or side effects could limit its use. It is not yet approved by the FDA.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Premier Health Neuroscience Institute

    Dayton, Ohio, 45409, United States

    Contact

    Contact

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

    Cleveland, Ohio, 44106, United States

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.